Aisling Capital Management LP
CIK: 0001766721SEC EDGAR →
Portfolio Value
$478.9B
Holdings
13
As of
Q4 2025
New Positions
14
Closed Positions
0
Portfolio Value History
Top 10 Holdings
| Rank | Stock | Shares | Value | % of Portfolio |
|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | 5,089,611 | $389.3B | 81.29% |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) | 1,316,806 | $27.7B | 5.78% |
| 3 | Monte Rosa Therapeutics Inc (GLUE) | 1,472,331 | $23.1B | 4.82% |
| 4 | Bicara Therapeutics Inc. (BCAX) | 568,919 | $9.6B | 2.00% |
| 5 | Compass Pathways Plc (CMPS) | 1,198,418 | $8.3B | 1.73% |
| 6 | BridgeBio Oncology Therapeutics (BBOT) | 564,625 | $7.1B | 1.48% |
| 7 | CalciMedica, Inc. (CALC) | 521,114 | $3.4B | 0.72% |
| 8 | Scholar Rock Holding Corporation (SRRK) | 77,031 | $3.4B | 0.71% |
| 9 | Biomea Fusion Inc (BMEA) | 2,048,757 | $2.5B | 0.53% |
| 10 | Urogen Pharma Ltd. (URGN) | 108,000 | $2.5B | 0.53% |
Quarterly Changes
Sector Breakdown
| Sector | # Holdings | Value | % |
|---|---|---|---|
| Healthcare | 13 | $478.9B | 100.0% |